Nisha Mohindra
Overview
Explore the profile of Nisha Mohindra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
986
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cella D, Kuharic M, Peipert J, Bedjeti K, Garcia S, Yanez B, et al.
J Am Med Inform Assoc
. 2024 Aug;
31(10):2190-2201.
PMID: 39093939
Objectives: To assess the use of a co-designed patient-reported outcome (PRO) clinical dashboard and estimate its impact on shared decision-making (SDM) and symptomatology in adults with advanced cancer or chronic...
2.
Tran S, Lin J, Galvez C, Rasmussen L, Pacheco J, Perottino G, et al.
Front Immunol
. 2024 Apr;
15:1331959.
PMID: 38558818
Introduction: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) poses a major clinical challenge to ICI therapy for cancer, with 13% of cases halting ICI therapy and ICI-IA being difficult to identify...
3.
Peipert J, Shaunfield S, Kaiser K, Moreno P, Fox R, Kircher S, et al.
Support Care Cancer
. 2023 Jul;
31(8):489.
PMID: 37486453
No abstract available.
4.
Peipert J, Shaunfield S, Kaiser K, Moreno P, Fox R, Kircher S, et al.
Support Care Cancer
. 2022 Dec;
31(1):37.
PMID: 36525100
Background: There is increasing interest in patient-reported measures of cancer treatment tolerability. A global measure of bother, the FACT GP5 item ("I am bothered by side effects of treatment") is...
5.
Perry L, Morken V, Peipert J, Yanez B, Garcia S, Barnard C, et al.
JMIR Res Protoc
. 2022 Sep;
11(9):e38461.
PMID: 36129747
Background: Patient-reported outcomes-symptoms, treatment side effects, and health-related quality of life-are important to consider in chronic illness care. The increasing availability of health IT to collect patient-reported outcomes and integrate...
6.
Ganti A, Loo B, Bassetti M, Blakely C, Chiang A, DAmico T, et al.
J Natl Compr Canc Netw
. 2021 Dec;
19(12):1441-1464.
PMID: 34902832
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and...
7.
Schulte B, Mohindra N, Milhem M, Attia S, Robinson S, Monga V, et al.
Br J Cancer
. 2021 May;
125(4):528-533.
PMID: 34050255
Background: Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs PFS. Prior studies of combinations of metronomic topotecan with pazopanib have indicated preclinical evidence of response in patients...
8.
Hassanzadeh C, Sita T, Savoor R, Samson P, Bradley J, Gentile M, et al.
J Thorac Dis
. 2020 Dec;
12(11):6690-6700.
PMID: 33282370
Background: Consolidation durvalumab improved overall survival (OS) in locally advanced non-small cell lung cancer (LA-NSCLC) treated with chemoradiotherapy (CRT) in the PACIFIC trial; however, pneumonitis was increased with durvalumab. We...
9.
Al-Adra D, Hammel L, Roberts J, Woodle E, Levine D, Mandelbrot D, et al.
Am J Transplant
. 2020 Sep;
21(2):475-483.
PMID: 32976703
Patients undergoing evaluation for solid organ transplantation (SOT) frequently have a history of malignancy. Only patients with treated cancer are considered for SOT but the benefits of transplantation need to...
10.
Al-Adra D, Hammel L, Roberts J, Woodle E, Levine D, Mandelbrot D, et al.
Am J Transplant
. 2020 Sep;
21(2):460-474.
PMID: 32969590
Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of malignancy. Although the cancer has been treated in these patients, the benefits of transplantation need to be...